Recombinant	JJ
human	JJ
serum-amyloid-P	NN
in	IN
healthy	JJ
volunteers	NNS
and	CC
patients	NNS
with	IN
pulmonary	JJ
fibrosis	NN
.	.

PRM-151	NN
,	,
recombinant	JJ
human	JJ
Pentraxin-2	NN
(	(
PTX-2	NN
)	)
also	RB
referred	VBD
to	TO
as	IN
serum-amyloid-P	NN
(	(
SAP	NN
)	)
,	,
is	VBZ
under	IN
development	NN
for	IN
treatment	NN
of	IN
fibrosis	NN
.	.

A	DT
First-in-Human	NN
(	(
FIH	NN
)	)
trial	NN
was	VBD
performed	VBN
to	TO
assess	VB
the	DT
safety	NN
,	,
tolerability	NN
,	,
and	CC
pharmacokinetics	NNS
of	IN
single	JJ
ascending	VBG
intravenous	JJ
doses	NNS
of	IN
PRM-151	NN
administered	VBN
to	TO
healthy	JJ
subjects	NNS
,	,
using	VBG
a	DT
randomized	VBN
,	,
blinded	VBN
,	,
placebo	NN
controlled	JJ
study	NN
design	NN
.	.

Each	DT
cohort	NN
included	VBD
three	CD
healthy	JJ
subjects	NNS
(	(
PRM-151	NN
:	:
placebo	NN
;	:
2:1	CD
)	)
.	.

SAP	NN
levels	NNS
were	VBD
assessed	VBN
using	VBG
a	DT
validated	VBN
ELISA	NN
method	NN
,	,
non-discriminating	JJ
between	IN
endogenous	JJ
and	CC
exogenous	JJ
SAP	NN
.	.

At	IN
a	DT
dose	NN
level	NN
of	IN
10	CD
mg/kg	NN
,	,
at	IN
which	WDT
a	DT
physiologic	JJ
plasma	NN
level	NN
of	IN
SAP	NN
was	VBD
reached	VBN
,	,
two	CD
additional	JJ
healthy	JJ
volunteers	NNS
and	CC
three	CD
pulmonary	JJ
fibrosis	NN
(	(
PF	NN
)	)
patients	NNS
were	VBD
enrolled	VBN
enabling	VBG
comparison	NN
of	IN
the	DT
pharmacokinetic	JJ
SAP	NN
profile	NN
between	IN
healthy	JJ
volunteers	NNS
and	CC
PF	NN
patients	NNS
.	.

In	IN
addition	NN
,	,
the	DT
percentage	NN
of	IN
fibrocytes	NNS
(	(
CD45	NN
+	CC
/	:
Procollagen-1	NN
+	CC
cells	NNS
)	)
in	IN
whole	JJ
blood	NN
samples	NNS
was	VBD
assessed	VBN
to	TO
demonstrate	VB
biological	JJ
activity	NN
of	IN
PRM-151	NN
in	IN
the	DT
target	NN
population	NN
.	.

PRM-151	NN
administration	NN
was	VBD
generally	RB
well	RB
tolerated	VBN
.	.

In	IN
two	CD
pulmonary	JJ
fibrosis	NN
patients	NNS
non-specific	JJ
,	,
transient	JJ
skin	NN
reactions	NNS
(	(
urticaria	NN
and	CC
erythema	NN
)	)
were	VBD
observed	VBN
.	.

PRM-151	NN
administration	NN
resulted	VBD
in	IN
a	DT
6-to	JJ
13-fold	RB
increase	VB
in	IN
mean	JJ
baseline	NN
plasma	NN
SAP	NN
levels	NNS
at	IN
dose	NN
levels	NNS
of	IN
5	CD
,	,
10	CD
,	,
and	CC
20	CD
mg/kg	NN
.	.

The	DT
estimated	VBN
t1/2	NN
of	IN
PRM-151	NN
in	IN
healthy	JJ
volunteers	NNS
was	VBD
30	CD
h.	NN
Pharmacokinetic	JJ
profiles	NNS
were	VBD
comparable	JJ
between	IN
healthy	JJ
volunteers	NNS
and	CC
PF	NN
patients	NNS
.	.

PRM-151	NN
administration	NN
resulted	VBD
in	IN
a	DT
30-50	CD
%	NN
decrease	NN
in	IN
fibrocyte	JJ
numbers	NNS
24	CD
h	NN
post-dose	NN
.	.

This	DT
suggests	VBZ
that	IN
administration	NN
of	IN
PRM-151	NN
may	MD
be	VB
associated	VBN
with	IN
a	DT
reduction	NN
of	IN
fibrocytes	NNS
in	IN
PF	NN
patients	NNS
,	,
a	DT
population	NN
for	IN
which	WDT
current	JJ
pharmacotherapeutic	JJ
options	NNS
are	VBP
limited	VBN
.	.

The	DT
pharmacological	JJ
action	NN
of	IN
PRM-151	NN
should	MD
be	VB
confirmed	VBN
in	IN
future	JJ
research	NN
.	.

